Evidence map›Paper›PMID 40956084›Full record

ArticleJournal of virology2025

An orally available 4

Xiaoqin Jian, Tianwen Hu, Huan Xu, Yuxi Wen, Yumin Zhang, Mengwei Xu, Xiaming Jiang, Junyuan Cao, Li Xiang, Jingshan Shen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaoqin Jian *State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID 0009-0009-7857-8826
Tianwen Hu *Vigonvita Shanghai Co., Ltd., Shanghai, China.
Huan XuDepartment of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yuxi WenDepartment of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yumin ZhangState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Mengwei XuState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Xiaming JiangState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Junyuan CaoState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Li XiangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jingshan ShenUniversity of Chinese Academy of Sciences, Beijing, China.
Guanghui TianVigonvita Shanghai Co., Ltd., Shanghai, China.ORCID 0000-0002-7988-5715
Gengfu XiaoState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID 0000-0001-9401-235X
Leike ZhangState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID 0000-0002-2593-2571

Funding

National Key Research and Development Program of China 2022YFC2303300National Natural Science Foundation of China U22A20379Science Fund for Distinguished Young Scholars of Hubei Province 2022CFA099Strategic Priority Research Program of Chinese Academy of Science XDB0490000
6 · The paper itself

Abstract

Bunyaviruses, a subset of segmented negative-sense RNA viruses, include pathogenic species capable of zoonotic transmission to humans via arthropod vectors and rodent hosts. Pathogenic bunyavirus infections can cause severe hemorrhagic fevers and other life-threatening diseases, posing threats to human health and social stability; however, therapeutic strategies for treating bunyavirus infections remain limited. Here, we report that VV251 hydrochloride salt (VV251), an optimized oral prodrug derivative of 4'-fluorouridine (EIDD-2794), exhibits potent efficacy against severe fever with thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus (LCMV) both

Indexed as

Antiviral AgentsLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusPhlebovirusProdrugsSevere Fever with Thrombocytopenia SyndromeUridineAdministration, OralAnimalsCell LineChlorocebus aethiopsDisease Models, AnimalFemaleHumansMacaca fascicularisMiceAntiviral AgentsProdrugsUridine4'-fluorouridineantiviral agentlymphocytic choriomeningitis virusnucleoside analogsevere fever with thrombocytopenia syndrome virus

Identifiers

PMID40956084
PMCPMC12548419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.